New drug AO-252 targets Hard-to-Treat cancers in early trial

NCT ID NCT06136884

Recruiting now Disease control Sponsor: A2A Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called AO-252 in people with advanced solid tumors, including those that have spread to the brain. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or stop them from growing. About 86 adults whose cancer has not responded to standard treatments will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer cancer metastatic neoplasm metastatic prostate carcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASES FROM SOLID TUMORS SOLID TUMOR MALIGNANCIES

Contacts and locations

Locations

Hollings Cancer Center - MUSC
RECRUITING

Charleston, South Carolina, 29425, United States
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Mary Crowley Cancer Research
RECRUITING

Dallas, Texas, 75230, United States
Next Oncology -Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Oklahoma Univeristy
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
The University of Texas M.D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.